IOBT Stock Overview
A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IO Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$2.10 |
| 52 Week Low | US$0.66 |
| Beta | 0.42 |
| 11 Month Change | -36.09% |
| 3 Month Change | -44.81% |
| 1 Year Change | -30.33% |
| 33 Year Change | -88.96% |
| 5 Year Change | n/a |
| Change since IPO | -94.57% |
Recent News & Updates
Recent updates
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
Jun 12
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Feb 10We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Jun 15We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Jan 20IO Biotech names new CFO
Oct 13We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
Sep 27IO Biotech GAAP EPS of -$0.64
Aug 11We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
Jun 14We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Feb 25Shareholder Returns
| IOBT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.6% | 4.3% | 1.6% |
| 1Y | -30.3% | 18.8% | 32.3% |
Return vs Industry: IOBT underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: IOBT underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| IOBT volatility | |
|---|---|
| IOBT Average Weekly Movement | 21.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IOBT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IOBT's weekly volatility has increased from 14% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 78 | MBZ Zocca | www.iobiotech.com |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers.
IO Biotech, Inc. Fundamentals Summary
| IOBT fundamental statistics | |
|---|---|
| Market cap | US$49.28m |
| Earnings (TTM) | -US$90.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs IOBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IOBT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$90.34m |
| Earnings | -US$90.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IOBT perform over the long term?
See historical performance and comparison